Menu
Search
|

Menu

Close
X

MediciNova Inc MNOV.OQ (NASDAQ Stock Exchange Global Market)

10.31 USD
-0.47 (-4.36%)
As of Oct 19
chart
Previous Close 10.78
Open 10.68
Volume 40,049
3m Avg Volume 30,107
Today’s High 10.70
Today’s Low 10.25
52 Week High 14.50
52 Week Low 5.86
Shares Outstanding (mil) 41.88
Market Capitalization (mil) 57,092.19
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.192
FY17
-0.338
FY16
-0.334
FY15
-0.151
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.14
Price to Sales (TTM)
vs sector
--
6.55
Price to Book (MRQ)
vs sector
6.96
4.00
Price to Cash Flow (TTM)
vs sector
--
21.51
Total Debt to Equity (MRQ)
vs sector
0.00
14.15
LT Debt to Equity (MRQ)
vs sector
0.00
11.31
Return on Investment (TTM)
vs sector
-24.00
12.83
Return on Equity (TTM)
vs sector
-25.23
14.95

EXECUTIVE LEADERSHIP

Jeffrey Himawan
Independent Chairman of the Board, Since 2007
Salary: --
Bonus: --
Yuichi Iwaki
President, Chief Executive Officer, Director, Since 2014
Salary: $533,503.00
Bonus: $266,751.00
Carla Reyes
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Geoffrey O'Brien
Vice President, Since 2013
Salary: $297,914.00
Bonus: $128,103.00
Masatsune Okajima
Vice President, Head - Japanese Office, Since 2006
Salary: $310,267.00
Bonus: $77,567.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

4275 Executive Sq Ste 650
LA JOLLA   CA   92037-1477

Phone: +1858.3731500

Medicinova, Inc. is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin). MN-166 is an oral, anti-inflammatory and neuroprotective agent. MN-166 is in development for the treatment of several neurological diseases, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, and substance dependence and addiction. MN-001 (tipelukast) is an orally bioavailable small molecule compound, which is used for the treatment of fibrotic diseases, such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis. MN-221 treats acute exacerbations of asthma through intravenous infusion, bypassing constricted airways to deliver the drug to the lungs. MN-029 is used for the treatment of solid tumor cancers.

SPONSORED STORIES